Form 8-K - Current report:
SEC Accession No. 0001104659-23-040181
Filing Date
2023-03-31
Accepted
2023-03-31 16:14:51
Documents
12
Period of Report
2023-03-29
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310837d2_8k.htm   iXBRL 8-K 26079
  Complete submission text file 0001104659-23-040181.txt   202438

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20230329.xsd EX-101.SCH 3072
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20230329_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20230329_pre.xml EX-101.PRE 22621
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2310837d2_8k_htm.xml XML 3713
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 23787806
SIC: 2834 Pharmaceutical Preparations